Abstract 1251P
Background
Neutrality trial aims to analyze the prognostic role of blood biomarkes such as NLR (neutrophils to lymphocytes ratio), SII (Systemic Inflammatory Index-NLR x platelets), dNLR (neutrophil to leukocytes - neutrophil ratio) and LIPI (Lung Immune Prognostic Index) in stage III NSCLC patients (pts) treated with radiochemotherapy (RT-CHT) followed by Durvalumab (Cohort A), and in pts treated with RT-CHT alone (Cohort B).
Methods
NEUTRALITY is a retrospective multicentric observational study (ESR-19-20410). Blood count tests were recorded at the end of RT-CHT for Cohort B and during Durvalumab course for Cohort A. Different cut-offs of NLR, dNLR and SII were considered, based on the median values observed. Three LIPI index groups were analyzed: good (dNLR ≤ 3 and LDH ≤ UNL), intermediate (dNLR>; 3 or LDH ≥ UNL) and poor (dNLR>; 3 and LDH ≥ UNL). We performed a Cox-Regression analysis to correlate these biomarkers to overall survival (OS) and progression-free survival (PFS).
Results
Overall 190 pts (96 in Cohort A and 94 in Cohort B) were enrolled from 35 Italian Centers. Details of pts are shown in the table. For cohort A, we observed a significant correlation between baseline NLR, SII and dNLR with PFS: p 0.017, p 0.03 and p 0.018, respectively. LIPI was found to correlate with PFS too, with a better PFS in the good group, as expected (p 0.04). No correlation was found between these biomarkers and PFS and OS in Cohort B. Table: 1251P
Patients characteristics
| Cohort A patients (%) 96 | Cohort B patients (%) 94 | |
| Sex MF | 62 (64.5%)34 (35.5%) | 66 (70%)28 (30%) |
| Smoke YesNo | 85 (88%)9 (12%) | 85 (90%)9 (10%) |
| Age years MedianRange | 68 y44-83 | 66 y42-84 |
| Histology AdenocarcinomaSquamocellularOthers | 54 (56%)39 (41%)3 (3%) | 49 (52%)39 (41%)6 (7%) |
| PD-L1 expression 01-49≥ 50Not tested | 12 (12.5%)41 (43%)30 (31%)13 (13.5%) | 11 (12%)15 (16%)9 (10%)59 (62%) |
| Stage disease IIIAIIIBIIIC | 35 (36.5%)48 (50%)13 (13.5%) | 39 (41%)44 (47%)11 (12%) |
| ECOG PS 012 | 59 (61.5%)35 (37.5%)1 (1%) | 60 (64%)34 (36%)0 |
Conclusions
Our analysis suggests that blood inflammatory biomarkers can have a prognostic role for stage III NSCLC treated as per Pacific regimen. Further analysis are still ongoing to compare the two cohorts.
Clinical trial identification
ESR-19-20410.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1324P - Durvalumab in treatment-naive, stage IV non-small cell lung cancer (NSCLC) patients (pts), with ECOG performance status (PS) 2-3 and high PD-L1 tumour expression: Results of IFCT-1802 SAVIMMUNE phase II trial
Presenter: Valerie Gounant
Session: Poster session 05
1325P - TRIDENT: Machine learning (ML) multimodal signatures to identify patients that would benefit most from tremelimumab (T) addition to durvalumab (D) + chemotherapy (CT) with data from the POSEIDON trial
Presenter: Ferdinandos Skoulidis
Session: Poster session 05
1326P - Clinical and genomic characteristics of advanced non-small cell lung cancer (aNSCLC) patients (pts) with long-term response to first-line (1L) immunotherapy: A real-world study
Presenter: Sameh Daher
Session: Poster session 05
1327P - Lung immune prognostic index (LIPI) as a guide for addition of chemotherapy in immunotherapy in elderly patients (Pts) with non-small cell lung cancer (NSCLC): NEJ057
Presenter: OSAMU HONJO
Session: Poster session 05
1328P - Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients
Presenter: Giulia Mazzaschi
Session: Poster session 05
1330P - Phase II study of pembrolizumab (pemb) plus plinabulin (plin) and docetaxel (doc) for patients (pts) with metastatic NSCLC after failure on first-line immune checkpoint inhibitor alone or combination therapy: Initial efficacy and safety results on Immune Re-sensitization
Presenter: Yan Xu
Session: Poster session 05
1331P - Efficacy, innovativeness, clinical trials, endpoints, and price of drugs with FDA approval for non-small cell lung cancer (NSCLC)
Presenter: Christoph Michaeli
Session: Poster session 05
1332P - Effects of immune checkpoint inhibitors for EGFR-wild/ALK-negative NSCLC patients with untreated brain metastases
Presenter: Toshihiko Iuchi
Session: Poster session 05
1333P - Prognostic value of circulating nucleosomes during treatment with or without immunotherapy in non-small lung cancer (NSCLC): Results from the NUCLEO-lung study
Presenter: Léa Payen
Session: Poster session 05